Ovation Acquires Aventis’ Sabril, Frisium; Projects 2006/07 Vigabatrin Launch
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Ovation believes it will be able to get Sabril through FDA in two to three years following its acquisition of North American rights to the antiepileptic from Aventis.